Stock Fundamentals

Company Information

Company Name
Merck & Company Inc
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
ISIN: US58933Y1055
CIK: 0000310158
CUSIP: 589339209
Currency: USD
Full Time Employees: 73,000
Phone: 908 740 4000
Fiscal Year End: December
IPO Date: Jan 13, 1978
Description:

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Address:

126 East Lincoln Avenue, Rahway, NJ, United States, 07065

Directors & Officers

Name Title Year Born
Mr. Robert M. Davis J.D. Chairman, President & CEO 1967
Ms. Caroline A. Litchfield Executive VP & CFO 1969
Ms. Jennifer L. Zachary J.D. Executive VP & General Counsel 1978
Dr. Dean Y. Li M.D., Ph.D. Executive VP & President of Merck Research Laboratories 1963
Mr. Dalton E. Smart III Senior VP of Finance, Principal Accounting Officer & Global Controller 1967
Mr. David Michael Williams Executive VP and Chief Information & Digital Officer 1969
Mr. Peter Dannenbaum Vice President of Investor Relations NA
Mr. Chirfi Guindo Executive Vice President of Strategic Access, Policy & Communications 1966
Ms. Betty D. Larson Executive VP & Chief Human Resources Officer 1976
Mr. Richard R. DeLuca Jr. Executive VP & President of Merck Animal Health 1963

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 10, 2026 Ro Khanna N/A Purchase N/A $117.14 N/A
Feb 09, 2026 Chirfi Guindo N/A Sale 10.00K $118.41 $1.18M
Feb 09, 2026 Jennifer Zachary N/A Sale 121.57K $119.15 $14.49M
Feb 06, 2026 David Michael Williams N/A Sale 5.00K $121.91 $609.55K
Feb 06, 2026 Johannes Jacobus Oosthuizen N/A Sale 15.00K $121.87 $1.83M
Feb 06, 2026 Richard R Deluca N/A Sale 37.69K $120.92 $4.56M
Feb 05, 2026 Chirfi Guindo N/A Sale 20.00K $121.88 $2.44M
Feb 04, 2026 Dean Y Li N/A Sale 15.09K $118.77 $1.79M
Feb 04, 2026 Josh Gottheimer N/A Purchase N/A $118.35 N/A
Feb 04, 2026 Robert M Davis N/A Sale 47.43K $118.04 $5.60M
Feb 04, 2026 Dalton E Smart III N/A Sale 6.40K $119.67 $765.89K
Feb 04, 2026 Caroline Litchfield N/A Sale 42.00K $119.61 $5.02M
Jan 13, 2026 Michael T. McCaul N/A Sale N/A $108.20 N/A
Dec 19, 2025 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $100.92 N/A
Dec 18, 2025 Julie Johnson N/A Sale N/A $100.76 N/A
Nov 18, 2025 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $96.61 N/A
Nov 13, 2025 Julie Johnson N/A Sale N/A $92.99 N/A
Nov 03, 2025 David Michael Williams N/A Sale 8.61K $83.59 $720.04K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 254.32M Dec 31, 2025 10.30% $0.39 0.87%
BlackRock Inc 225.83M Mar 31, 2026 9.14% $0.47 3.07%
State Street Corp 119.33M Mar 31, 2026 4.83% $0.50 -0.60%
Wellington Management Company LLP 84.31M Mar 31, 2026 3.41% $1.89 -2.45%
Geode Capital Management, LLC 59.56M Mar 31, 2026 2.41% $0.44 -0.82%
JPMorgan Chase & Co 52.97M Mar 31, 2026 2.14% $0.40 81.41%
Charles Schwab Investment Management Inc 49.77M Mar 31, 2026 2.01% $0.91 2.47%
Morgan Stanley - Brokerage Accounts 47.63M Mar 31, 2026 1.93% $0.35 5.98%
FMR Inc 44.52M Mar 31, 2026 1.80% $0.28 9.01%
NORGES BANK 37.98M Dec 31, 2025 1.54% $0.43 5.18%
Bank of America Corp 30.77M Mar 31, 2026 1.25% $0.27 10.48%
Northern Trust Corp 27.09M Mar 31, 2026 1.10% $0.43 -0.53%
Fisher Asset Management, LLC 26.44M Mar 31, 2026 1.07% $1.08 6.28%
T. Rowe Price Associates, Inc. 23.04M Mar 31, 2026 0.93% $0.32 22.87%
Amvescap Plc. 21.86M Mar 31, 2026 0.88% $0.40 6.37%
UBS Asset Mgmt Americas Inc 20.41M Mar 31, 2026 0.83% $0.51 5.05%
The Goldman Sachs Group Inc 20.13M Mar 31, 2026 0.82% $0.28 4.06%
Legal & General Group PLC 19.54M Mar 31, 2026 0.79% $0.54 -1.20%
Bank of New York Mellon Corp 18.71M Mar 31, 2026 0.76% $0.41 -2.35%
Franklin Resources Inc 16.27M Mar 31, 2026 0.66% $0.48 1.26%

Shares Statistics

Shares Outstanding: 2.47B
Shares Float: 2.47B
% Insiders: 6.10%
% Institutions: 8,200.60%
Short % Float: 1.18%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 78.78M 3.19% ▲ 0.30% Apr 30, 2026
2 Vanguard 500 Index Investor 64.36M 2.61% ▲ 1.83% Apr 30, 2026
3 iShares Core S&P 500 ETF 32.10M 1.30% ▲ 0.29% Apr 30, 2026
4 Fidelity 500 Index 31.70M 1.28% ▲ 0.35% Mar 31, 2026
5 Schwab US Dividend Equity ETF™ 29.86M 1.21% ▲ 0.09% Apr 30, 2026
6 State Street® SPDR® S&P 500® ETF 29.67M 1.20% ▲ 0.33% Apr 30, 2026
7 Vanguard Value Index Inv 22.92M 0.93% ▲ 0.29% Apr 30, 2026
8 State Street®HlthCrSelSectSPDR®ETF 17.88M 0.72% ▼ 0.98% Apr 30, 2026
9 Vanguard Health Care Inv 17.79M 0.72% ▼ 1.78% Mar 31, 2026
10 Vanguard Dividend Appreciation ETF 13.94M 0.56% ▲ 0.28% Apr 30, 2026

Valuation Metrics

Enterprise Value: $327.86B
Trailing P/E: 32.58
Forward P/E: 22.78

Financial Highlights

Market Cap: $285.64B
EBITDA: $29.52B
P/E Ratio: $32.58
PEG Ratio: $5.36
Book Value: $18.58
Dividend/Share: $3.28
Dividend Yield: 2.85%
Earnings/Share: $3.55
Profit Margin: 13.59%
Operating Margin: 38.60%
ROA (TTM): 12.58%
ROE (TTM): 18.94%
Revenue (TTM): $65.77B
Revenue/Share (TTM): $26.42
Earnings Growth (YOY): -19.30%
Revenue Growth (YOY): 4.90%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 1.54x 0.94x 0.62x 17.31x 1.69x
2024-12-31 1.36x 0.81x 0.60x 15.91x 1.45x
2023-12-31 1.25x 0.94x 0.65x 2.58x 5.12x
2022-12-31 1.47x 0.67x 0.58x 19.00x 1.45x
2021-12-31 1.27x 0.87x 0.64x 16.38x 1.87x
2020-12-31 1.02x 1.27x 0.72x 6.68x 3.15x
2019-12-31 1.24x 1.02x 0.69x 8.88x 2.32x
2018-12-31 1.17x 0.94x 0.67x 11.57x 1.79x
2017-12-31 1.33x 0.71x 0.61x 9.01x 2.04x
2016-12-31 1.78x 0.62x 0.58x 7.94x 2.30x
2015-12-31 1.55x 0.59x 0.56x 11.23x 2.13x
2014-12-31 1.77x 0.44x 0.50x 9.13x 0.87x
2013-12-31 2.00x 0.50x 0.50x 9.57x 1.88x
2012-12-31 1.90x 0.39x 0.48x 13.83x 1.25x
2011-12-31 2.04x 0.32x 0.46x 11.98x 1.13x
2010-12-31 1.86x 0.33x 0.46x 4.69x 1.83x
2009-12-31 1.82x 0.30x 0.45x 8.78x 0.95x
2008-12-31 1.33x 0.33x 0.55x 24.24x 0.53x
2007-12-31 1.23x 0.32x 0.57x N/A 0.75x
2006-12-31 1.20x 0.39x 0.55x N/A 1.15x
2005-12-31 1.59x 0.45x 0.55x N/A 1.07x
2004-12-31 1.15x 0.40x 0.54x N/A 0.84x
2003-12-31 1.20x 0.44x 0.52x N/A 0.69x
2002-12-31 1.16x 0.47x 0.51x N/A 0.83x
2001-12-31 1.12x 0.55x 0.53x N/A 0.85x
2000-12-31 1.38x 0.47x 0.50x N/A 0.65x
1999-12-31 1.29x 0.22x 0.53x N/A 0.32x
1998-12-31 1.69x 0.05x 0.48x N/A 0.08x
1997-12-31 1.47x 0.07x 0.47x N/A 0.13x
1996-12-31 1.60x 0.05x 0.41x N/A 0.10x
1995-12-31 1.51x 0.04x 0.41x N/A 0.08x
1994-12-31 1.27x 0.01x 0.44x N/A 0.03x
1993-12-31 0.97x 0.17x 0.44x N/A 0.40x
1992-12-31 1.22x 0.16x 0.49x N/A 0.22x
1991-12-31 1.53x 0.07x 0.42x N/A 0.10x
1990-12-31 1.33x 0.21x 0.45x N/A 0.27x
1989-12-31 1.79x 0.09x 0.40x N/A 0.13x
1988-12-31 1.78x 0.16x 0.53x N/A 0.22x
1987-12-31 1.36x 0.40x 0.63x N/A 0.54x
1986-12-31 1.77x 0.15x 0.50x N/A 0.30x
1985-12-31 1.92x 0.13x 0.46x N/A 0.32x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MRK.US!